Detalles de la búsqueda
1.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34167578
2.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796151
3.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31730009
4.
Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and haematological tumours: protocol for a randomised controlled trial.
BMJ Open
; 12(1): e055814, 2022 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35017254
5.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer
; 142: 18-28, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33212418
6.
Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples.
J Exp Clin Cancer Res
; 39(1): 120, 2020 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32580740
7.
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples.
J Exp Clin Cancer Res
; 39(1): 95, 2020 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32460897
8.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Eur J Cancer
; 128: 17-26, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32109847
9.
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
J Immunother Cancer
; 8(2)2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33154150
10.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Oncoimmunology
; 9(1): 1710389, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002308
11.
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Clin Lung Cancer
; 20(4): 237-247.e1, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30885550
12.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
J Immunother Cancer
; 7(1): 57, 2019 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30813970
Resultados
1 -
12
de 12
1
Próxima >
>>